Yıl: 2010 Cilt: 25 Sayı: 1 Sayfa Aralığı: 1 - 11 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Assessment of Rheumatoid Arthritis in Clinical Care

Öz:
Kas-iskelet sistemi hastalığı olan bireylerin kantitatif izlemi her klinik uygulamanın parçası olmalıdır. Kantitatif izlem,hekimin hastanın klinik durumu ve zaman içindeki değişimini değerlendirme kapasitesini arttırır ve daha doğru klinik kararlar vermesini sağlar. Ayrıca ardışık hastalarda rutin veri toplama, randomize klinik çalışmalardan elde edilebilecek bilgiden ötede uzun süre boyunca hasta gruplarının analizini kolaylaştırır.
Anahtar Kelime:

Konular: Romatoloji

Romatoid Artritin Klinik Deÿerlendirmesi

Öz:
Quantitative clinical monitoring of patients with musculoskeletal conditions should be included in the infrastructure of every clinical practice. Quantitative monitoring improves the physician's capacity to assess and document a patient's clinical status and changes over time, which leads to greater accuracy in the underlying rationale for clinical decisions. Furthermore, routine data collection in consecutive patients facilitates analyses of groups of patients over long periods in usual care, beyond information that can be obtained from randomized clinical trials.
Anahtar Kelime:

Konular: Romatoloji
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Smith T. Questions on clinical trials (editorial). Br Med J 1983; 287: 569.
  • Luukkainen R, Kajander A, Isomäki H. Treatment of rheumatoid arthritis (letter). Br Med J 1978; 2: 1501.
  • Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
  • Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34: 316-21.
  • Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
  • Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
  • Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, Ter Borg EJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
  • Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815-22.
  • Fransen J, Moens HB, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised contolled trial. Ann Rheum Dis 2005; 64: 1294-8.
  • Sokka T, Kautiainen H, Häkkinen K, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J
  • Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-19.
  • Uhlig T, Heiberg T, Mowinckel P, Kvien TK. Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994-2004. Ann Rheum Dis 2008; 67: 1710-5.
  • Pincus T, Callahan LF. Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34: 196-9.
  • Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 2003; 17: 753-81.
  • Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 2006; 33: 834-7.
  • Cooperating Clinics Committee of the American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965; 8: 302-35.
  • Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; New Series 37: 393-406.
  • American Rheumatism Association. Dictionary of the rheumatic diseases vol. I: signs and symptoms. New York: Contact Associates International; 1982.
  • Decker JL. American Rheumatism Association nomenclature and classification of arthritis and rheumatism. Arthritis Rheum 1983; 26: 1029-32.
  • Bombardier C, Tugwell P, Sinclair A, Dok C, Anderson G, Buchanan WW. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol 1982; 9: 798-801.
  • Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Care Res 2003; 49: 59-63.
  • Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21(Suppl 41): 86-9.
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
  • American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007; 57: 193-202.
  • Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989; 32: 531-7.
  • Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-8.
  • Pincus T, Brooks RH, Callahan LF. A proposed standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. JRheumatol 1999; 26: 473-80.
  • Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
  • Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-46.
  • Pinals RS, Masi AT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
  • Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994; 21: 1227-37.
  • Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273-81.
  • van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
  • Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis-a systematic review. Clin Exp Rheumatol 2005; 23: S69-S76.
  • Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: Diagnostic accuracy of anti- cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
  • Ursum J, Bos WH, van DN, Dijkmans BA, van SD. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010; 12: R8.
  • Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
  • Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983; 26: 1346-53.
  • Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220-30.
  • Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol 2005; 32: 1432-9.
  • Pincus T, Yazici Y, Bergman M. Development of a multi- dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol 2005; 23: S19-S28.
  • Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
  • Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991; 18: 1298-306.
  • Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: Physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol 1992; 45: 127-38.
  • Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. J Rheumatol 1998; 25: 2108-17.
  • Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 1681-5.
  • Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29: 488-93.
  • Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1072-82.
  • Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford health assessment questionnaire functional disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1480-8.
  • Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991; 18: 1307-12.
  • Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
  • Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. Arthritis Care Res 1996; 9: 463-72.
  • Callahan LF, Pincus T, Huston JW, III, Brooks RH, Nance EP, Jr., Kaye JJ. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381-94.
  • Söderlin MK, Nieminen P, Hakala M. Functional status predicts mortality in a community based rheumatoid arthritis population. J Rheumatol 1998; 25: 1895-9.
  • Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004; 63: 494-7.
  • Sokka T, Hakkinen A. Poor physical fitness and performance as predictors of mortality in normal populations and patients with rheumatic and other diseases. Clin Exp Rheumatol 2008; 26(5 Suppl 5): 14-20.
  • Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self- administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum 1995; 38: 795-8.
  • Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SMM, Hetland ML et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66: 1491-6.
  • Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-81.
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
  • van der Heijde DMFM, van't Hof MA, van Riel PLCM, Theunisse LM, Lubberts EW, van Leeuwen MA et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
  • van der Heijde DMFM, van't Hof M, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
  • Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
  • Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
  • Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold KP et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-R806.
  • Makinen H, Kautiainen H, Hannonen P, Sokka T. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA). J Rheumatol 2008; 35: 1522-7.
  • Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600-6.
  • Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47: 345-9.
  • Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008; 35: 2136-47.
  • Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625-30.
  • Pincus T, Amara I, Koch GG. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005; 52: 1031-6.
  • Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J
  • Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004; 22(Suppl 35): S50-S56.
  • Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36-41.
  • Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706-20.
  • Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis: changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum 1982; 25: 540-9.
  • Sharp JT. Radiographic evaluation of the course of articular disease. Clin Rheum Dis 1983; 9: 541-57.
  • Larsen A. A Radiological Method for Grading the Severity of Rheumatoid Arthritis. Espoo: Meder-Offset; 1974.
  • Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol [Diagn] (Stockh) 1977; 18: 481-91.
  • van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 743-5.
  • Landewe R, van der Heijde D. Radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S63-S68.
  • van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van't Hof MA, van Rijswijk MH et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
  • Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in longterm studies? J Rheumatol 1995; 22: 1974-5.
  • Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997; 24: 1285-7.
  • Rau R, Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol 1995; 22: 1976-82.
  • Rau R, Wassenberg S, Herborn G, Perschel WT, Freitag G. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 2608-15.
  • Pincus T, Larsen A, Brooks RH, Kaye J, Nance EP, Callahan LF. Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker Stage, Kaye Modified Sharp Score, and Larsen Score. J Rheumatol 1997; 24: 2106-12.
  • Pincus T, Sokka T. A three-page Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from patients and health professionals in standard clinical care and clinical research. Best Pract Res Clin Rheumatol 2007; 21: 677-85.
  • Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91.
  • Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989; 110: 259-66.
  • Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther 2009; 11: R7.
  • Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68: 1666-72.
  • Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM et al. Reevaluation of the Role of Duration of Morning Stiffness in the Assessment of Rheumatoid Arthritis Activity. J Rheumatol 2009; 36: 2435-42.
  • Naranjo A, Sokka T, Descalzo M, Calvo-Alén J, Horslev- Petersen K, Luukkainen RK et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST- RA study. Arthritis Res Ther 2008; 10: R30-Epub ahead of print.
  • Sokka T, Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S58-S62.
  • Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez- Almazor M, Pincus T et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. Omeract IV: Outcome measures in rheumatology. Cancun, Mexico, April 16-20, 1998. J Rheumatol 1999; 26: 484-9.
  • Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev- Petersen K, Luukkainen RK et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty- four countries. Arthritis Rheum 2008; 58: 2642-51.
  • Sokka T, Hakkinen A, Kautiainen H, Maillefert JF, Toloza S, Mork Hansen T et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 2008; 59: 42-50.
  • Verstappen SM, Jacobs JW, Huisman AM, van Rijthoven AW, Sokka T, Bijlsma JW. Functional Health Assessment Questionnaire (HAQ) and Psychological HAQ Are Associated with and Predicted by Different Factors in Rheumatoid Arthritis. J Rheumatol 2007; 34: 1837-40.
  • Gogus F, Yazici Y, Yazici H. Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort. Clin Exp Rheumatol 2005; 23: 681-4.
  • Waaler H, Starky C. What is the best indicator of health care? World Health Forum 1984; 5: 276-9.
  • Tresserras R, Canela J, Alvarez J, Sentis J, Salleras L. Infant mortality, per capita income, and adult illiteracy: an ecological approach. Am J Public Health 1992; 82: 435-8.
  • Janssen F, Kunst AE, Mackenbach JP. Association between gross domestic product throughout the life course and old-age mortality across birth cohorts: parallel analyses of seven European countries, 1950-1999. Soc Sci Med 2006; 63: 239-54.
  • Micheli A, Coebergh JW, Mugno E, Massimiliani E, Sant M, Oberaigner W et al. European health systems and cancer care. Ann Oncol 2003; 14(suppl 5): v41-v60.
  • Sokka T. Long-term outcomes of rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 284-90.
  • Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission. Clin Exp Rheumatol 2006; 24 (S43): S22-S28.
  • Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 46-52.
  • Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007; 34: 1670-3.
  • Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
  • Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007; 17: 28-32.
  • Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006; 1069: 212-22.
  • Miller A, Green M, Robinson D. Short rule for calculating normal erythrocyte sedimentation rate. Br Med J 1983; 286: 266.
  • Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008; 18: 228-39.
  • Blair SN, Kohl HW3, Paffenbarger RS, Jr., Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262: 2395-401.
  • Work group recommendations: 2002 Exercise and Physical Activity Conference, St. Louis, Missouri. Session V: evidence of benefit of exercise and physical activity in arthritis. Arthritis Rheum 2003; 49: 453-4.
  • ACR Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines of the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
  • Häkkinen A, Sokka T, Kotaniemi A, Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001; 44: 515-22.
  • Stenstrom CH. Therapeutic exercise in rheumatoid arthritis. Arthritis Care Res 1994; 7: 190-7.
  • Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551-6.
  • Mäkisara GL, Mäkisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol 1982; 1: 117-25.
  • Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48: 59-63.
  • Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S71-4.
  • Verstappen SM, Jacobs JW, Hyrich KL. Effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007; 34: 2126-8.
  • Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3046-54.
  • Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 716-22.
  • Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35: 206-15.
  • Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009; 48: 1283-9.
  • Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009; 61: 1592-600.
  • Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007; 34: 2211-7.
  • Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008; 59: 1082-9.
  • Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo- Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006; 65: 924-8.
  • Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Rheumatoid arthritis (RA) patients treated with TNF-antagonists increase their participation in the work-force - potential for significant long-term indirect cost gains. Data from a population-based registry. Ann Rheum Dis 2010; 69: 126-31.
  • Eberhardt K. Very early intervention is crucial to improve work outcome in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1104-6.
  • Chung CP, Sokka T, Arbogast P, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006; 65: 1653-7.
  • Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010; 12: R42. 11
APA SOKKA T (2010). Assessment of Rheumatoid Arthritis in Clinical Care. , 1 - 11.
Chicago SOKKA Tuulikki Assessment of Rheumatoid Arthritis in Clinical Care. (2010): 1 - 11.
MLA SOKKA Tuulikki Assessment of Rheumatoid Arthritis in Clinical Care. , 2010, ss.1 - 11.
AMA SOKKA T Assessment of Rheumatoid Arthritis in Clinical Care. . 2010; 1 - 11.
Vancouver SOKKA T Assessment of Rheumatoid Arthritis in Clinical Care. . 2010; 1 - 11.
IEEE SOKKA T "Assessment of Rheumatoid Arthritis in Clinical Care." , ss.1 - 11, 2010.
ISNAD SOKKA, Tuulikki. "Assessment of Rheumatoid Arthritis in Clinical Care". (2010), 1-11.
APA SOKKA T (2010). Assessment of Rheumatoid Arthritis in Clinical Care. Turkish Journal of Rheumatology(.)Archives of Rheumatology, 25(1), 1 - 11.
Chicago SOKKA Tuulikki Assessment of Rheumatoid Arthritis in Clinical Care. Turkish Journal of Rheumatology(.)Archives of Rheumatology 25, no.1 (2010): 1 - 11.
MLA SOKKA Tuulikki Assessment of Rheumatoid Arthritis in Clinical Care. Turkish Journal of Rheumatology(.)Archives of Rheumatology, vol.25, no.1, 2010, ss.1 - 11.
AMA SOKKA T Assessment of Rheumatoid Arthritis in Clinical Care. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2010; 25(1): 1 - 11.
Vancouver SOKKA T Assessment of Rheumatoid Arthritis in Clinical Care. Turkish Journal of Rheumatology(.)Archives of Rheumatology. 2010; 25(1): 1 - 11.
IEEE SOKKA T "Assessment of Rheumatoid Arthritis in Clinical Care." Turkish Journal of Rheumatology(.)Archives of Rheumatology, 25, ss.1 - 11, 2010.
ISNAD SOKKA, Tuulikki. "Assessment of Rheumatoid Arthritis in Clinical Care". Turkish Journal of Rheumatology(.)Archives of Rheumatology 25/1 (2010), 1-11.